Actinium Pharmaceuticals (ATNM)
(Delayed Data from AMEX)
$8.73 USD
-0.17 (-1.91%)
Updated May 10, 2024 04:00 PM ET
After-Market: $8.72 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Actinium Pharmaceuticals, Inc. [ATNM]
Reports for Purchase
Showing records 81 - 91 ( 91 total )
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Healthcare Monthly Catalyst Tracker; Does The Election Matter to Biotech?
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare: Inaugural Healthcare Monthly; Catalysts Galore
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Actimab-A Phase II Gets Going; Initial Data Not Too Far Off
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - The A to Z of HSCT: InvestorÂ’s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Totally Rad Man; Providing More AML and Beyond Options; Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Initiation of Coverage - Totally Rad Man; Providing More AML and Beyond Options; rating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Actinium Pharmaceuticals, Inc.
Industry: Medical - Drugs
Encouraging Phase 1 Data Defines Next Step in AML Program
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A